P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Conditions:   Breast Cancer;   Ovarian Cancer;   Non Small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Renal Cell Carcinoma;   Nasopharyngeal Cancer;   Head and Neck Squamous Cell Carcinoma;   Gastric Cancer
Interventions:   Biological: P-MUC1C-ALLO1 CAR-T cells;   Drug: Rimiducid
Sponsor:   Poseida Therapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 8, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments